Effect of ghrelin on septic shock in rats

Acta Pharmacologica Sinica

Volumn 24, Issue 1, 2003, Pages 45-49

  Chang, Lin ^c   Du, Jun Bao ^a   Gao, Lian Ru ^b   Pang, Yong Zheng ^c   Tang, Chao Shu ^c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NAVY GENERAL HOSPITAL   (China)

^c NONE

Author keywords

Ghrelin; Hemodynamics; Septic shock

Indexed keywords

ADENOSINE TRIPHOSPHATE; GHRELIN; GLUCOSE; LACTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMORAL VEIN; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HEMODYNAMICS; LACTATE BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; METABOLIC DISORDER; MORTALITY; NONHUMAN; RAT; SEPTIC SHOCK;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR AGENTS; HEMODYNAMIC PROCESSES; LACTIC ACID; MALE; MYOCARDIUM; PEPTIDE HORMONES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 0037231079     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
2. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227-32.
3. Papotti M, Ghe C, Cassoni P, Catapano F, Deghenghi R, Ghigo E, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 2000; 85: 3803-7.
4. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: 1483-7.
5. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104: 2034-8.
6. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430-5.
7. Tang C, Liu MS. Initial externalization followed by internalization of beta-adrenergic receptors in rat heart during sepsis. Am J Physiol 1996; 270 (1 Pt 2): R254-63.
8. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock: a review of laboratory models and a proposal. J Surg Res 1980; 29: 189-201.
9. Zimmer HG. Measurement of left ventricular hemodynamic parameters in close-chest rats under control and various pathophysiologic conditions. Basic Res Cardiol 1983; 78: 77-84.
10. Osterziel KJ, Blum WF, Strohm O, Dietz R. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J Clin Endocrinol Metab 2000; 85: 1533-9.
11. Giustina A, Volterrani M, Manelli F, Desenzani P, Poiesi C, Lorusso R, et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J 1999; 137: 1035-43.
12. O'Leary MJ, Quinton N, Ferguson CN, Preedy VR, Ross RJ, Hinds CJ, et al. In rats with sepsis, the acute fall in IGF-1 is associated with an increase in circulating growth hormone-binding protein levels. Intensive Care Med 2000; 26: 1547-52.
13. Fukushima R, Saito H, Inoue T, Fukatsu K, Inaba T, Han I, et al. Prophylactic treatment with growth hormone and insulin-like growth factor I improve systemic bacterial clearance and survival in a murine model of burn-induced gut-derived sepsis. Burns 1999; 25: 425-30.
14. Rossoni G, Locatelli V, Gennaro Colonna Vd, Muller EE, Berti F. Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium. Pharmacol Res 2000; 42: 129-36.
15. Ivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, et al. Hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000; 141: 60-6.
16. Locatelli V, Rossoni G, Schweiger F, Torsello A, de Gennaro Colonna V, Bernareggi M, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999; 140: 4024-31.